Visceral Leishmaniasis Treatment, Italy

Visceral Leishmaniasis Treatment, Italy

First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change...

Full description

Bibliographic Details
Main Authors: Luigi Gradoni, Marina Gramiccia, Aldo Scalone
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2003-12-01
Series:Emerging Infectious Diseases
Subjects:
Visceral leishmaniasis
drug treatment
pentavalent antimony
amphotericin B
Italy
Online Access:https://wwwnc.cdc.gov/eid/article/9/12/03-0178_article
id doaj-a9de6dfc345f441093d37ea4a663d9e2
record_format Article
spelling doaj-a9de6dfc345f441093d37ea4a663d9e22020-11-25T02:35:53ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592003-12-019121617162010.3201/eid0912.030178Visceral Leishmaniasis Treatment, ItalyLuigi GradoniMarina GramicciaAldo ScaloneFirst-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.https://wwwnc.cdc.gov/eid/article/9/12/03-0178_articleVisceral leishmaniasisdrug treatmentpentavalent antimonyamphotericin BItaly
collection DOAJ
language English
format Article
sources DOAJ
author Luigi Gradoni
Marina Gramiccia
Aldo Scalone
spellingShingle Luigi Gradoni
Marina Gramiccia
Aldo Scalone
Visceral Leishmaniasis Treatment, Italy
Emerging Infectious Diseases
Visceral leishmaniasis
drug treatment
pentavalent antimony
amphotericin B
Italy
author_facet Luigi Gradoni
Marina Gramiccia
Aldo Scalone
author_sort Luigi Gradoni
title Visceral Leishmaniasis Treatment, Italy
title_short Visceral Leishmaniasis Treatment, Italy
title_full Visceral Leishmaniasis Treatment, Italy
title_fullStr Visceral Leishmaniasis Treatment, Italy
title_full_unstemmed Visceral Leishmaniasis Treatment, Italy
title_sort visceral leishmaniasis treatment, italy
publisher Centers for Disease Control and Prevention
series Emerging Infectious Diseases
issn 1080-6040
1080-6059
publishDate 2003-12-01
description First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
topic Visceral leishmaniasis
drug treatment
pentavalent antimony
amphotericin B
Italy
url https://wwwnc.cdc.gov/eid/article/9/12/03-0178_article
work_keys_str_mv AT luigigradoni visceralleishmaniasistreatmentitaly
AT marinagramiccia visceralleishmaniasistreatmentitaly
AT aldoscalone visceralleishmaniasistreatmentitaly
_version_ 1724802786084782080

Similar Items